Traders should prepare for the upcoming earnings release and webcast, particularly watching for revenue from Olverembatinib and Lisaftoclax, progress in U.S. regulatory trials (POLARIS and GLORA studies), and any updates on partnerships with AstraZeneca, Merck, or Pfizer.
Price Chart
Executive Summary
Ascentage Pharma announced it will release its full year 2025 unaudited financial results on March 25–26, 2026, with investor webcasts scheduled in both Mandarin and English. The press release contains no actual financial data, only logistical details for the upcoming earnings event.
Key Facts
- Ascentage Pharma will release full year 2025 unaudited results on March 25, 2026 (EDT) / March 26, 2026 (HKT).
- Management will host two investor webcasts: one in Mandarin on March 25 and one in English on March 26, 2026.
- No financial results, guidance, or business updates were disclosed in this announcement.
- The company highlighted its commercial-stage oncology pipeline, including Olverembatinib and Lisaftoclax, and ongoing global Phase III trials.
Financial Impact
No financial data disclosed — impact cannot be assessed at this time
Risk Factors
- Lack of U.S. FDA approval for key drugs despite ongoing trials could limit near-term revenue growth.
- Forward-looking statements are subject to significant risks including clinical trial failures, regulatory delays, and competition.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3253683 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.45 (+3.55%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.45 (+3.55%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.45 (+5.17%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.45 (−0.52%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.45 (+10.80%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.45 (−8.34%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.45 (−8.06%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.45 (−18.21%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.45 (−15.90%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.45 (−19.70%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers